|hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer|
C Camps, FM Buffa, S Colella, J Moore, C Sotiriou, H Sheldon, AL Harris, ...
Clinical cancer research 14 (5), 1340-1348, 2008
|Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization|
M Korpal, BJ Ell, FM Buffa, T Ibrahim, MA Blanco, T CeliÓ-Terrassa, ...
Nature medicine 17 (9), 1101, 2011
|miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors|
P Moskwa, FM Buffa, Y Pan, R Panchakshari, P Gottipati, RJ Muschel, ...
Molecular cell 41 (2), 210-220, 2011
|microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer|
FM Buffa, C Camps, L Winchester, CE Snell, HE Gee, H Sheldon, ...
Cancer research 71 (17), 5635-5645, 2011
|Regulation of autophagy by ATF4 in response to severe hypoxia|
T Rzymski, M Milani, L Pike, F Buffa, HR Mellor, L Winchester, I Pires, ...
Oncogene 29 (31), 4424-4435, 2010
|MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU|
E Favaro, A Ramachandran, R McCormick, H Gee, C Blancher, M Crosby, ...
PloS one 5 (4), e10345, 2010
|Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers|
SC Winter, FM Buffa, P Silva, C Miller, HR Valentine, H Turley, KA Shah, ...
Cancer research 67 (7), 3441-3449, 2007
|The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis|
HE Gee, FM Buffa, C Camps, A Ramachandran, R Leek, M Taylor, M Patil, ...
British journal of cancer 104 (7), 1168-1177, 2011
|Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene|
FM Buffa, AL Harris, CM West, CJ Miller
British journal of cancer 102 (2), 428-435, 2010
|Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation|
K Bensaad, E Favaro, CA Lewis, B Peck, S Lord, JM Collins, KE Pinnick, ...
Cell reports 9 (1), 349-365, 2014
|Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells|
E Favaro, K Bensaad, MG Chong, DA Tennant, DJP Ferguson, C Snell, ...
Cell metabolism 16 (6), 751-764, 2012
|hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer|
HE Gee, C Camps, FM Buffa, S Patiar, SC Winter, G Betts, J Homer, ...
Cancer 116 (9), 2148-2158, 2010
|Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival|
H Choudhry, A Albukhari, M Morotti, S Haider, D Moralli, J Smythies, ...
Oncogene 34 (34), 4482-4490, 2015
|The histone demethylase JMJD2B is regulated by estrogen receptor α and hypoxia, and is a key mediator of estrogen induced growth|
J Yang, AM Jubb, L Pike, FM Buffa, H Turley, D Baban, R Leek, KC Gatter, ...
Cancer research 70 (16), 6456-6466, 2010
|MicroRNA-10b and breast cancer metastasis|
HE Gee, C Camps, FM Buffa, S Colella, H Sheldon, JM Gleadle, ...
Nature 455 (7216), E8-E9, 2008
|Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER|
T Van Den Beucken, E Koch, K Chu, R Rupaimoole, P Prickaerts, ...
Nature communications 5 (1), 1-13, 2014
|A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis|
M Masiero, FC Sim§es, HD Han, C Snell, T Peterkin, E Bridges, ...
Cancer cell 24 (2), 229-241, 2013
|Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis|
AM Jubb, FM Buffa, AL Harris
Journal of cellular and molecular medicine 14 (1‐2), 18-29, 2010
|Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer|
D Generali, FM Buffa, A Berruti, MP Brizzi, L Campo, S Bonardi, A Bersiga, ...
|A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer|
A Eustace, N Mani, PN Span, JJ Irlam, J Taylor, GNJ Betts, H Denley, ...
Clinical cancer research 19 (17), 4879-4888, 2013